Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers

Video

Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.

In an interview with CancerNetwork®, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlighted key findings from a basket trial presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that examined the use of erdafitinib (Balversa) in gastrointestinal (GI) cancers.

Transcript:

One is a basket trial for patients with FGFR alterations, [including] driver mutations or fusions, with [treatment with] a drug called erdafitinib, which is an FGFR inhibitor. We presented the data at this ASCO in which we did a basket trial in non-bladder cancers, [including] a lot of GI cancers, glioblastoma, and other cancers. What we saw was that there was an overall response rate in this unselected tumor agnostic population of about 30%. What was even more exciting was that our patients with cholangiocarcinoma had response rates of up to 50% and patients with pancreatic cancer—a very hard to treat malignancies [with] outcomes that are not that great—had response rates of 30%. We were very excited about presenting the data at ASCO.

Reference

Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. J Clin Oncol. 2022;40(suppl 16):3007. doi: 10.1200/JCO.2022.40.16_suppl.3007

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Related Content